Compare Amphastar Pharmaceuticals Inc (AMPH) vs Docusign Inc (DOCU) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

DOCU trades at $49.18, up 0.86% today, with a bullish technical signal from moving averages and strong support near $47. The company reported Q1 2026 EPS of $1.09, beating estimates, and maintains robust gross margins of 79.4%. Recent partnerships with Perplexity and Slack highlight growth in intelligent agreement management, while revenue guidance for 2026 stands at $3.3 billion.

Outlook remains positive with a consensus price target of $55.40, though high valuation multiples (P/E 31.94) and overbought RSI levels pose near-term risks. Competitive pressures in SaaS and reliance on subscription growth are key watchpoints for investors seeking exposure to DOCU's profitable expansion.